Last reviewed · How we verify
Hydroxycarbamide — Competitive Intelligence Brief
phase 3
Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Hydroxycarbamide (Hydroxycarbamide) — University of Birmingham.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Hydroxycarbamide TARGET | Hydroxycarbamide | University of Birmingham | phase 3 | Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9 | ||
| Siklos | Siklos | Theravia | marketed | Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9 | ||
| Xromi | Xromi | Nova Laboratories Limited | marketed | Carbonic anhydrase 2, Carbonic anhydrase 5A, mitochondrial, Carbonic anhydrase 9 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Hydroxycarbamide CI watch — RSS
- Hydroxycarbamide CI watch — Atom
- Hydroxycarbamide CI watch — JSON
- Hydroxycarbamide alone — RSS
Cite this brief
Drug Landscape (2026). Hydroxycarbamide — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroxycarbamide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing